Tweet
J Med Virol. 2018 Nov 15. doi: 10.1002/jmv.25358. [Epub ahead of print]
Umifenovir Susceptibility Monitoring and Characterization of Influenza Viruses Isolated during ARBITR Clinical Study.
Leneva IA1, Falynskova IN1, Makhmudova NR1, Poromov AA1,2, Yatsyshina SB3, Maleev VV3.
Author information
Abstract
Antiviral drugs can play a significant role in the control of influenza. Umifenovir (Arbidol) is licensed and widely used in Russia for the prophylaxis and/or treatment of influenza. We evaluated the susceptibility to umifenovir of reference influenza A and B viruses and influenza A viruses isolated from patients in the ARBITR clinical trial in 2012-2014 seasons. Using an MDCK cell-based ELISA, we showed that the replication of antigenically dominant human influenza A and B viruses was efficiently inhibited by umifenovir. The wild-type А/Perth/265/2009 (H1N1)pdm09, A/Fukui/45/2004 (H3N2) and B/Perth/211/2001 viruses and their oseltamivir-resistant counterparts were susceptible to umifenovir among in vitro laboratory assays. All 18 clinical isolates of influenza A viruses obtained before and during therapy were susceptible to umifenovir with EC50 ranging from 8.4 ? 1.1 to 17.4 ? 5.4 ?M. No molecular markers of umifenovir resistance were identified in influenza viruses isolate d from patients at 3, 5 and 7 days after initiation of therapy. None of the viruses isolated before and during umifenovir therapy displayed reduced susceptibility to neuraminidase (NA) inhibitors. Thus, umifenovir is effective against influenza viruses circulating in 2012-2014 seasons, and therapy did not lead to the emergence of drug-resistant variants. This article is protected by copyright. All rights reserved.
KEYWORDS:
chemotherapy; drug specificity; influenza virus; resistance
PMID: 30431664 DOI: 10.1002/jmv.25358
Umifenovir Susceptibility Monitoring and Characterization of Influenza Viruses Isolated during ARBITR Clinical Study.
Leneva IA1, Falynskova IN1, Makhmudova NR1, Poromov AA1,2, Yatsyshina SB3, Maleev VV3.
Author information
Abstract
Antiviral drugs can play a significant role in the control of influenza. Umifenovir (Arbidol) is licensed and widely used in Russia for the prophylaxis and/or treatment of influenza. We evaluated the susceptibility to umifenovir of reference influenza A and B viruses and influenza A viruses isolated from patients in the ARBITR clinical trial in 2012-2014 seasons. Using an MDCK cell-based ELISA, we showed that the replication of antigenically dominant human influenza A and B viruses was efficiently inhibited by umifenovir. The wild-type А/Perth/265/2009 (H1N1)pdm09, A/Fukui/45/2004 (H3N2) and B/Perth/211/2001 viruses and their oseltamivir-resistant counterparts were susceptible to umifenovir among in vitro laboratory assays. All 18 clinical isolates of influenza A viruses obtained before and during therapy were susceptible to umifenovir with EC50 ranging from 8.4 ? 1.1 to 17.4 ? 5.4 ?M. No molecular markers of umifenovir resistance were identified in influenza viruses isolate d from patients at 3, 5 and 7 days after initiation of therapy. None of the viruses isolated before and during umifenovir therapy displayed reduced susceptibility to neuraminidase (NA) inhibitors. Thus, umifenovir is effective against influenza viruses circulating in 2012-2014 seasons, and therapy did not lead to the emergence of drug-resistant variants. This article is protected by copyright. All rights reserved.
KEYWORDS:
chemotherapy; drug specificity; influenza virus; resistance
PMID: 30431664 DOI: 10.1002/jmv.25358